US2013164811A1PendingUtilityA1
Dna damaging agents in combination with tyrosine kinase inhibitors
Est. expiryFeb 4, 2014(expired)· nominal 20-yr term from priority
A61K 41/17A61K 31/7072A61K 31/40A61K 31/7048A61K 31/70A61K 31/704A61N 5/10A61K 41/0023A61K 31/365
66
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to the signalling pathways connecting DNA damage, such as that induced by ionizing radiation or alkylating agents, and phosphorylation by tyrosine kinases.
Claims
exact text as granted — not AI-modified1 - 21 . (canceled)
22 . A process of selectively activating the lyn family of Src-like tyrosine kinases in a cell that expresses the lyn gene, the process comprising exposing the cell to an effective dose from a Cesium-137 source.
23 . The process of claim 22 , wherein the lyn family of Src-like tyrosine kinases comprises p56/p53 lyn .
24 . The process of claim 22 , wherein the Cesium-137 source has photon energy with a photopeak at 662 keV.
25 . The process of claim 22 , wherein the dose of Cesium-137 is at least 50 cGy.
26 . The process of claim 22 , wherein the dose of Cesium-137 is between 50 and 500 cGy.
27 . The process of claim 22 , wherein the dose of Cesium-137 is 200 cGy.
28 . The process of claim 22 , wherein the cell is a part of a human subject exposed to Cesium-137 source.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.